Bio-Rad Launches ddSEQ™ Single-Cell 3′ RNA-Seq Kit for Single-Cell Gene Expression

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the ddSEQ™ Single-Cell 3′ RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research. 

Designed to be run on Bio-Rad’s droplet-based single-cell isolation system, the ddSEQ Cell Isolator, the ddSEQ Single-Cell 3′ RNA-Seq Kit delivers high-quality single-cell 3′ RNA-Seq libraries in a fast, efficient, and affordable workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses. The subsequent QC, analysis, and reporting of data generated from the ddSEQ Single-Cell 3′ RNA-Seq Kit is enabled by the accompanying Omnition v1.1 Analysis Software, a robust pipeline analysis tool. These valuable insights into single-cell transcription and gene expression support a broad range of research fields such as oncology, immunology, neurology, and stem cell biology. 

“The new ddSEQ™ Single-Cell 3′ RNA-Seq Kit expands our NGS library preparation portfolio and is a further reflection of our commitment to provide researchers with innovative technologies to support molecular biology, oncology, and drug discovery research,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Used with our ddSEQ Cell Isolator, the new kit and Omnition v1.1 Analysis Software presents a more cost-effective solution for single-cell transcription and gene expression studies, facilitating seamless integration into a broad spectrum of research applications and empowering research teams to undertake more experiments within the same budget.”  

To learn more about the ddSEQ Single-Cell 3′ RNA-Seq Kit, visit www.bio-rad.com/ddSEQ3scRNA-SeqKit

SourceBio-Rad

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version